Table. Genotype and allele frequencies for rs11155313.
In the original GWAS rs11155313 minor allele frequency was increased in patients in Tier 1 (0.32 versus 0.27; OR 1.67; P-value 2.17 × 10-3) and decreased in patients in Tier 2 (0.27 versus 0.37; OR 0.58; P-value 1.54 × 10-5). Odds ratios in the present study correspond to an increase in one copy of the minor allele (G). Allele and genotype frequencies have been adjusted to account for individuals missing genotype data. For the matched US, Irish, and Norwegian series, estimated odds ratios and P-values result from single variable conditional logistic regression models. For the Canadian series, the estimated odds ratio and P-value results from a logistic regression model adjusted for age and gender.
| Series/rs11155313 | AA | AG | GG | G (%) | OR (95% CI) | P |
|---|---|---|---|---|---|---|
| US | ||||||
| Controls | 118 | 103 | 17 | 137 (29) | 1.39 (1.03 – 1.88) | 0.032 |
| Patients | 103 | 111 | 28 | 167 (35) | ||
| Canada | ||||||
| Controls | 122 | 95 | 14 | 123 (27) | 1.41 (1.07-1.85) | 0.014 |
| Patients | 201 | 193 | 50 | 293 (33) | ||
| Norway | ||||||
| Controls | 136 | 125 | 27 | 179 (31) | 1.15 (0.89 – 1.49) | 0.270 |
| Patients | 125 | 131 | 35 | 201 (35) | ||
| Ireland | ||||||
| Controls | 92 | 73 | 12 | 97 (27) | 1.44 (1.03 – 2.02) | 0.034 |
| Patients | 80 | 74 | 26 | 126 (35) | ||
| Combined | ||||||
| Controls | 468 | 396 | 70 | 536 (27) | 1.30 (1.13-1.48) | <0.001 |
| Patients | 509 | 509 | 139 | 787 (33) |